Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | BCL6 | P41182 | 3/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125560 | 1.00 | PTPN11 (0.40) | PTPN11HCRTR1HCRTR2WDR5BCL6 | |
| SCHEMBL4134620 | 0.86 | PTPN11 (0.44) | PTPN11HCRTR1HCRTR2BCL6RBP4 | |
| SCHEMBL4134623 | 0.86 | PTPN11 (0.44) | PTPN11HCRTR1HCRTR2BCL6RBP4 | |
| SCHEMBL6016338 | 0.85 | PTPN11 (0.43) | PTPN11WDR5BCL6RBP4NCOR2 | |
| SCHEMBL6016341 | 0.85 | PTPN11 (0.43) | PTPN11WDR5BCL6RBP4NCOR2 | |
| SCHEMBL4119980 | 0.83 | ALDH1A1 (0.42) | — | |
| SCHEMBL4126105 | 0.83 | PTPN11 (0.43) | PTPN11HCRTR1HCRTR2BCL6RBP4 | |
| SCHEMBL4126108 | 0.83 | PTPN11 (0.43) | PTPN11HCRTR1HCRTR2BCL6RBP4 | |
| Piperazine SCHEMBL6016696 | 0.82 | ALDH1A1 (0.41) | — | |
| SCHEMBL4130912 | 0.82 | TACR1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | claimed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | claimed |
| EP-1187815-B1 | 4-PHENYL-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | EP | claimed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | claimed |
| US-6274588-B1 | NEUROKININ OR SUBSTANCE P ANTAGONISTS; CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDES; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. | 2001-08-14 | — | — | US | claimed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2018-03-15 | — | — | US | disclosed |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2016-02-04 | — | — | US | disclosed |
| US-9186404-B2 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2015-11-17 | — | — | US | disclosed |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2009-10-08 | — | — | US | disclosed |
| EP-1187815-B1 | 4-PHENYL-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2005-05-19 | — | — | US | disclosed |
| US-6274588-B1 | NEUROKININ OR SUBSTANCE P ANTAGONISTS; CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDES; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. | 2001-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071333-A1 | BRAIN, SPINAL, AND NERVE INJURY TREATMENT | TACR1, TACR2, NPSR1 | PTPN11 2144/4885HCRTR1 398/4885HCRTR2 459/4885 |
| US-20050107380-A1 | Brain, spinal and nerve injury treatment | TACR1, TACR2, NMUR1 | PTPN11 2294/4885HCRTR1 427/4885HCRTR2 480/4885 |
| US-20160030474-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | PTPN11 2294/4885HCRTR1 427/4885HCRTR2 480/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | PTPN11 2144/4885HCRTR1 398/4885HCRTR2 459/4885 |
| US-20090253698-A1 | Brain, Spinal and Nerve Injury Treatment | TACR1, TACR2, NMUR1 | PTPN11 2294/4885HCRTR1 427/4885HCRTR2 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.